Amylyx Pharmaceuticals (AMLX) Set to Announce Earnings on Thursday

Amylyx Pharmaceuticals (NASDAQ:AMLX) will post its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect Amylyx Pharmaceuticals to post earnings of $0.24 per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings results on Thursday, February 22nd. The company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.20 by $0.03. The company had revenue of $108.45 million for the quarter, compared to the consensus estimate of $106.40 million. Amylyx Pharmaceuticals had a net margin of 12.94% and a return on equity of 12.39%. During the same quarter last year, the firm posted ($0.65) earnings per share. On average, analysts expect Amylyx Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Amylyx Pharmaceuticals Stock Down 1.0 %

NASDAQ:AMLX opened at $1.97 on Wednesday. The company has a market cap of $133.98 million, a P/E ratio of 2.81 and a beta of -0.68. Amylyx Pharmaceuticals has a fifty-two week low of $1.70 and a fifty-two week high of $30.50. The firm’s 50 day moving average is $4.81 and its two-hundred day moving average is $11.51.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Amylyx Pharmaceuticals in a research note on Monday, April 8th. Leerink Partnrs downgraded shares of Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, March 11th. Mizuho downgraded shares of Amylyx Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, March 18th. Evercore ISI reissued an “in-line” rating on shares of Amylyx Pharmaceuticals in a research note on Friday, March 8th. Finally, Robert W. Baird downgraded shares of Amylyx Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Monday, March 11th. Six analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Amylyx Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $32.67.

Insider Buying and Selling

In related news, CEO Joshua B. Cohen sold 4,135 shares of Amylyx Pharmaceuticals stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $18.73, for a total transaction of $77,448.55. Following the sale, the chief executive officer now owns 3,023,002 shares of the company’s stock, valued at approximately $56,620,827.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Joshua B. Cohen sold 4,135 shares of Amylyx Pharmaceuticals stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $18.73, for a total transaction of $77,448.55. Following the sale, the chief executive officer now owns 3,023,002 shares of the company’s stock, valued at approximately $56,620,827.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gina Mazzariello sold 2,838 shares of Amylyx Pharmaceuticals stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $18.76, for a total transaction of $53,240.88. Following the sale, the insider now directly owns 46,245 shares in the company, valued at approximately $867,556.20. The disclosure for this sale can be found here. Insiders have sold 10,305 shares of company stock valued at $193,098 in the last quarter. Company insiders own 11.70% of the company’s stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.